High Penetrance Deleterious Mutations In Blinding Glaucoma
Funder
National Health and Medical Research Council
Funding Amount
$1,345,055.00
Summary
This project aims to identify the genes most commonly mutated in individuals with advanced glaucoma. Identification of such genes will lead to improved understanding of glaucoma pathogenesis, a better ability to predict risk, and the identification of drug targets for novel therapies.
Functional Analysis Of Recently Identified Novel Glaucoma Genes.
Funder
National Health and Medical Research Council
Funding Amount
$519,918.00
Summary
Glaucoma is the commonest cause of irreversible blindness in the world. Recently, through genetic studies in cohorts of blinding glaucoma cases from Australia, our group has found that variants in two genes increase the risk of blinding glaucoma. This project will investigate how these genes contribute to pathological changes in the optic nerve and retina, at the back of the eye, that lead to glaucoma. This knowledge will be useful for developing new strategies to treat glaucoma.
The Contribution Of Aberrant Wnt Signalling To Neuronal And Vascular Pathology In Retinal Disease
Funder
National Health and Medical Research Council
Funding Amount
$561,342.00
Summary
Neuronal damage and vascular abnormalities are features shared by many retinal diseases. We will use a novel transgenic model to study the contributions of aberrant Wnt signalling in retinal neuronal and vascular pathology, and also, to test strategies for neuroprotection and inhibition of vascular abnormalities. Success in the project may identify novel therapeutic targets leading to safer and more effective treatments for retinal diseases.
Anti-vascular Endothelial Growth Factor-B As A Biologic For Treating Eye Disease
Funder
National Health and Medical Research Council
Funding Amount
$464,295.00
Summary
We plan to show that an engineered antibody fragment against vascular endothelial growth factor-B is an effective therapeutic drug for two eye diseases, corneal neovascularization and age-related macular degeneration. The innovative aspects of this approach are that it may be safer, and have a different spectrum of activity, than existing ophthalmic anti-angiogenic agents. Furthermore, it may be effective for corneal disease when administered as an eye-drop.